Autolus reported preliminary unaudited net product revenue for AUCATZYL® of $24 million for Q4 2025 and $75 million for the full year.
The company projects AUCATZYL® net product revenue of $120-$135 million for 2026.
Focus in 2026 includes driving top-line growth, optimizing manufacturing, and advancing clinical trials in pediatric hem-oncology and autoimmune indications.
Successful AUCATZYL® Launch
Full year sales exceeded expectations in the U.S., with positive real-world data from the ROCCA consortium.
Revenue Expectations
Preliminary unaudited revenue for 2025: $75 million. 2026 revenue guidance: $120-$135 million.
Pipeline Progress
Advancements in CATULUS, LUMINA, and BOBCAT trials to expand obe-cel's utility in different indications.
- Autolus establishes strong revenue with $75 million in 2025 and projects further growth in 2026.
- Real-world data supports AUCATZYL® efficacy, driving future revenue and market expansion.
- Pipeline advancements show promise in expanding therapeutic applications of obe-cel in pediatric and autoimmune diseases.
Autolus's successful commercial-stage achievements in 2025 set the stage for continued growth in 2026 through revenue projections and pipeline advancements.